EVM
NAGE

Eaton Vance Management’s Niagen Bioscience NAGE Stock Holding History

Eaton Vance Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57
Closed – – 2774
2021
Q4 		$0 Hold
57
– – ﹤0.01% 2892
2021
Q3 		$0 Hold
57
– – ﹤0.01% 2761
2021
Q2 		$1K Buy
+57
New +$497 ﹤0.01% 2780

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eaton Vance Management's NAGE Position: Q1 2022 in Review

Eaton Vance Management sold out of Niagen Bioscience (NAGE) in Q1 2022, closing a stake of 57 shares.

Eaton Vance Management first reported a position in NAGE in Q2 2021 and held it in 3 quarters. The position peaked at $1K in Q2 2021. 82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

  • Eaton Vance Management reported no remaining Niagen Bioscience position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 57 Niagen Bioscience shares in Q1 2022.
  • Eaton Vance Management first reported a position in Niagen Bioscience in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Niagen Bioscience position peaked at $1K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.